GlassScriptPhysician profile
David Robert Demartini
NPI 1437134855
$1,156.36
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $278.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $235.44 | 2019-2020 | |
| Allergan, INC. | $204.26 | 2019-2020 | |
| Johnson & Johnson Surgical Vision, INC. | $171.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $129.28 | 2019 | |
| Aerie Pharmaceuticals, INC. | $122.34 | 2019-2020 | |
| Dompe US, INC. | $87.42 | 2019 | |
| Biotissue Holdings INC. | $86.44 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $53.53 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.74 | 2019 | |
| Shire North American Group INC | $21.70 | 2019 | |
| Mallinckrodt Enterprises LLC | $20.01 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Demartini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.